Oric Pharmaceuticals (ORIC) Competitors $10.14 -0.01 (-0.10%) Closing price 04:00 PM EasternExtended Trading$10.08 -0.06 (-0.59%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. MTSR, KYMR, VKTX, MOR, CRNX, ALVO, MLTX, CPRX, IMVT, and HCMShould you be buying Oric Pharmaceuticals stock or one of its competitors? The main competitors of Oric Pharmaceuticals include Metsera (MTSR), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), MoonLake Immunotherapeutics (MLTX), Catalyst Pharmaceuticals (CPRX), Immunovant (IMVT), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Oric Pharmaceuticals vs. Its Competitors Metsera Kymera Therapeutics Viking Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech MoonLake Immunotherapeutics Catalyst Pharmaceuticals Immunovant HUTCHMED Oric Pharmaceuticals (NASDAQ:ORIC) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations. Is ORIC or MTSR more profitable? Metsera's return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oric PharmaceuticalsN/A -51.14% -46.29% Metsera N/A N/A N/A Do analysts rate ORIC or MTSR? Oric Pharmaceuticals currently has a consensus price target of $19.17, suggesting a potential upside of 89.02%. Metsera has a consensus price target of $55.00, suggesting a potential upside of 104.61%. Given Metsera's higher probable upside, analysts plainly believe Metsera is more favorable than Oric Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ORIC or MTSR? In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Metsera. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 2 mentions for Metsera. Metsera's average media sentiment score of 0.96 beat Oric Pharmaceuticals' score of 0.77 indicating that Metsera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metsera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ORIC or MTSR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOric PharmaceuticalsN/AN/A-$127.85M-$1.87-5.42MetseraN/AN/A-$209.13MN/AN/A Do institutionals & insiders have more ownership in ORIC or MTSR? 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.6% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryOric Pharmaceuticals beats Metsera on 5 of the 9 factors compared between the two stocks. Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricOric PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$865.03M$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-5.4221.1726.2519.74Price / SalesN/A262.85405.80109.12Price / CashN/A41.8936.4957.06Price / Book2.947.237.925.37Net Income-$127.85M-$55.05M$3.15B$248.34M7 Day Performance-3.34%-0.74%0.95%1.25%1 Month Performance22.76%6.27%5.25%5.41%1 Year Performance32.72%0.19%32.63%18.06% Oric Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICOric Pharmaceuticals4.2752 of 5 stars$10.14-0.1%$19.17+89.0%+43.6%$865.03MN/A-5.4280MTSRMetseraN/A$29.00-2.0%$55.00+89.7%N/A$3.11BN/A0.0081Gap DownKYMRKymera Therapeutics3.08 of 5 stars$46.29+0.9%$59.82+29.2%+46.2%$2.99B$47.07M-14.93170Trending NewsInsider TradeAnalyst RevisionGap UpVKTXViking Therapeutics4.1442 of 5 stars$24.86-4.4%$87.15+250.6%-50.0%$2.92BN/A-21.6220MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.5641 of 5 stars$29.91-0.8%$74.56+149.3%-35.8%$2.82B$1.04M-7.83210ALVOAlvotech3.7211 of 5 stars$9.13-2.4%$18.00+97.2%-25.0%$2.82B$491.98M24.681,032MLTXMoonLake Immunotherapeutics2.2605 of 5 stars$44.87+3.1%$78.71+75.4%+7.3%$2.78BN/A-19.512CPRXCatalyst Pharmaceuticals4.9321 of 5 stars$22.12-1.6%$32.83+48.4%+40.1%$2.74B$491.73M14.0980Positive NewsIMVTImmunovant1.9422 of 5 stars$15.47-2.1%$38.33+147.8%-39.4%$2.70BN/A-5.65120HCMHUTCHMED1.7685 of 5 stars$15.21+2.5%$19.00+24.9%-12.1%$2.59B$630.20M0.001,811Positive News Related Companies and Tools Related Companies Metsera Competitors Kymera Therapeutics Competitors Viking Therapeutics Competitors MorphoSys Competitors Crinetics Pharmaceuticals Competitors Alvotech Competitors MoonLake Immunotherapeutics Competitors Catalyst Pharmaceuticals Competitors Immunovant Competitors HUTCHMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
